Zhejiang Garden BiopharmaceuticalLtd Performance dei guadagni passati
Il passato criteri di controllo 3/6
Zhejiang Garden BiopharmaceuticalLtd's earnings have been declining at an average annual rate of -6.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 13.2% per year. Zhejiang Garden BiopharmaceuticalLtd's return on equity is 9.1%, and it has net margins of 25.1%.
Informazioni chiave
-6.3%
Tasso di crescita degli utili
-9.1%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 10.9% |
| Tasso di crescita dei ricavi | 13.2% |
| Rendimento del capitale proprio | 9.1% |
| Margine netto | 25.1% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2024 |
Aggiornamenti sulle prestazioni recenti
Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Profits May Not Reveal Underlying Issues
Oct 24
Why Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 22Recent updates
Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Profits May Not Reveal Underlying Issues
Oct 24Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet
Sep 29Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
Sep 08Why Investors Shouldn't Be Surprised By Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) 27% Share Price Surge
Jun 30Is Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) A Risky Investment?
May 31Subdued Growth No Barrier To Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) With Shares Advancing 27%
May 06Why Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 22Ripartizione dei ricavi e delle spese
Come Zhejiang Garden BiopharmaceuticalLtd guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 24 | 1,134 | 285 | 298 | 91 |
| 30 Jun 24 | 1,038 | 217 | 304 | 90 |
| 31 Mar 24 | 1,108 | 232 | 349 | 95 |
| 31 Dec 23 | 1,095 | 192 | 376 | 91 |
| 30 Sep 23 | 1,237 | 179 | 437 | 87 |
| 30 Jun 23 | 1,274 | 204 | 466 | 83 |
| 31 Mar 23 | 1,348 | 284 | 466 | 70 |
| 01 Jan 23 | 1,418 | 384 | 447 | 70 |
| 30 Sep 22 | 1,427 | 466 | 428 | 66 |
| 30 Jun 22 | 1,385 | 461 | 414 | 63 |
| 31 Mar 22 | 1,329 | 543 | 338 | 69 |
| 01 Jan 22 | 1,117 | 484 | 258 | 59 |
| 30 Sep 21 | 937 | 409 | 192 | 58 |
| 30 Jun 21 | 847 | 420 | 117 | 53 |
| 31 Mar 21 | 699 | 293 | 97 | 44 |
| 31 Dec 20 | 659 | 263 | 93 | 45 |
| 30 Sep 20 | 630 | 261 | 71 | 35 |
| 30 Jun 20 | 645 | 277 | 71 | 38 |
| 31 Mar 20 | 617 | 276 | 70 | 42 |
| 31 Dec 19 | 718 | 344 | 68 | 43 |
| 30 Sep 19 | 763 | 392 | 71 | 47 |
| 30 Jun 19 | 758 | 384 | 76 | 44 |
| 31 Mar 19 | 661 | 315 | 74 | 36 |
| 01 Jan 19 | 660 | 307 | 68 | 31 |
| 30 Sep 18 | 585 | 252 | 57 | 32 |
| 30 Jun 18 | 508 | 208 | 47 | 31 |
| 31 Mar 18 | 569 | 232 | 49 | 25 |
| 01 Jan 18 | 420 | 130 | 53 | 22 |
| 30 Sep 17 | 416 | 120 | 62 | 6 |
| 30 Jun 17 | 403 | 103 | 62 | 0 |
| 31 Mar 17 | 355 | 60 | 72 | 0 |
| 31 Dec 16 | 329 | 44 | 68 | 0 |
| 30 Sep 16 | 272 | 29 | 58 | 0 |
| 30 Jun 16 | 239 | 17 | 62 | 0 |
| 31 Mar 16 | 178 | 10 | 47 | 0 |
| 31 Dec 15 | 151 | 12 | 48 | 0 |
| 30 Sep 15 | 152 | 22 | 51 | 0 |
| 30 Jun 15 | 158 | 33 | 47 | 0 |
| 31 Mar 15 | 163 | 38 | 50 | 0 |
| 31 Dec 14 | 159 | 37 | 49 | 0 |
| 30 Sep 14 | 158 | 40 | 49 | 0 |
| 31 Dec 13 | 184 | 36 | 45 | 0 |
Guadagni di qualità: 300401 has a large one-off gain of CN¥86.9M impacting its last 12 months of financial results to 30th September, 2024.
Margine di profitto in crescita: 300401's current net profit margins (25.1%) are higher than last year (14.5%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 300401's earnings have declined by 6.3% per year over the past 5 years.
Accelerare la crescita: 300401's earnings growth over the past year (59.3%) exceeds its 5-year average (-6.3% per year).
Guadagni vs Settore: 300401 earnings growth over the past year (59.3%) exceeded the Pharmaceuticals industry -1.2%.
Rendimento del capitale proprio
ROE elevato: 300401's Return on Equity (9.1%) is considered low.